Genprex, Inc. Stock price

Equities

GNPX

US3724462037

Biotechnology & Medical Research

Delayed Nasdaq 12:05:12 2024-03-28 pm EDT 5-day change 1st Jan Change
2.79 USD +2.94% Intraday chart for Genprex, Inc. -8.61% -70.00%
Sales 2023 * - Sales 2024 * - Capitalization 4.03M
Net income 2023 * -32M Net income 2024 * -34M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 31
Yield 2023 *
-
Yield 2024 *
-
Free-Float 76.93%
More Fundamentals * Assessed data
Dynamic Chart
HC Wainwright Initiates Genprex With Buy Rating, $10 Price Target MT
Genprex Closes $6.5 Million Registered Direct Offering of Shares, Accompanying Warrants MT
Genprex Launches $6.5 Million Securities Offering; Shares Fall MT
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers MT
Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers CI
Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators CI
Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer CI
Genprex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Investors Weigh -2- DJ
Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics CI
North American Morning Briefing : Nasdaq Futures -2- DJ
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs CI
Genprex, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Genprex's Small-Cell Lung Cancer Treatment Gets FDA Orphan Drug Designation; Shares Rise MT
Genprex Closes $7.5 Million Offering MT
More news
1 day+2.40%
1 week-8.61%
Current month-35.81%
1 month-33.81%
3 months-70.00%
6 months-81.85%
Current year-70.00%
More quotes
1 week
2.50
Extreme 2.5
3.27
1 month
2.50
Extreme 2.5
5.41
Current year
2.50
Extreme 2.5
14.40
1 year
2.50
Extreme 2.5
46.00
3 years
2.50
Extreme 2.5
198.00
5 years
2.50
Extreme 2.5
308.80
10 years
2.50
Extreme 2.5
778.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 09-03-31
Director of Finance/CFO 42 09-03-31
Chief Tech/Sci/R&D Officer - 21-11-30
Members of the board TitleAgeSince
Director/Board Member 67 20-03-17
Chief Executive Officer 67 09-03-31
Director/Board Member 51 20-03-17
More insiders
Date Price Change Volume
24-03-28 2.79 +2.94% 5 507
24-03-27 2.71 -1.09% 50,445
24-03-26 2.74 -8.67% 57,381
24-03-25 3 -1.96% 76,447
24-03-22 3.06 +1.32% 25,885

Delayed Quote Nasdaq, March 28, 2024 at 12:05 pm EDT

More quotes
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on the development of gene-based therapies for patients with unmet medical needs. The Company's lead oncology drug candidate, REQORSA Immunogen therapy drug (quaratusugene ozeplasmid), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA consists of the TUSC2 gene-expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (its ONCOPREX Nanoparticle Delivery System). The Company is also using a different gene therapy delivery system in developing its pre-clinical diabetes candidates, GPX-002 and GPX-003. Its diabetes gene therapy is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.71 USD
Average target price
320 USD
Spread / Average Target
+11,708.12%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Genprex, Inc. - Nasdaq